ORGANOVO HOLDINGS
Organovo is focused on delivering breakthrough three-dimensional biology capabilities to create tissue on demand for research and surgical applications. As the first company with a three-dimensional tissue technology that works across tissue types, they are meeting the promise of regenerative medicine to fill unmet medical needs.
ORGANOVO HOLDINGS
Industry:
Biotechnology Medical Therapeutics
Founded:
2007-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.organovo.com
Total Employee:
51+
Status:
Active
Contact:
(858)550-9994
Email Addresses:
[email protected]
Total Funding:
112.29 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Eric Del Balso
Eric Del Balso investment in Post-IPO Equity - Organovo Holdings
SternAegis
SternAegis investment in Post-IPO Equity - Organovo Holdings
Spencer Trask & Co
Spencer Trask & Co investment in Post-IPO Equity - Organovo Holdings
Michael Brams
Michael Brams investment in Series A - Organovo Holdings
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-18 | Organovo Welcomes New Sr. Vice President of Strategy and Business Development |
Official Site Inspections
http://www.organovo.com Semrush global rank: 2.35 M Semrush visits lastest month: 7.92 K
- Host name: 52.18.197.104.bc.googleusercontent.com
- IP address: 104.197.18.52
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Organovo Holdings" on Search Engine
Investor Overview | Organovo Holdings, Inc.
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for …See details»
Organovo Holdings - Crunchbase Company Profile
Legal Name Organovo Holdings Inc. Stock Symbol NASDAQ:ONVO. Company Type For Profit. Contact Email [email protected]. Phone Number (858)550-9994. Organovo is …See details»
Organovo - Wikipedia
Organovo is an early-stage medical laboratory and research company which designs and develops functional, three dimensional human tissue (also known as 3D bioprinting …See details»
Leadership Team - Organovo, Inc.
With decades of leadership experience in the life science industry, our team fosters an ethos of innovation to develop regenerative medicine therapies aimed at treating a range …See details»
Organovo Announces Target Validation Ahead of Schedule, …
Nov 15, 2022 Organovo plans to advance at least one target program to medicinal chemistry by the end of 2022 to build a proprietary new drug for Crohn’s disease.See details»
Investor Presentations | Organovo Holdings, Inc.
May 3, 2024 Crohn’s & Colitis Congress Presentation – (Presenter: Fabrice Piu) January 25, 2024. H.C. Wainwright Global Investment Conference – (Presenter: Keith Murphy) …See details»
Investors - Organovo, Inc.
© 2024 Organovo Holdings Inc. 11555 Sorrento Valley Road, Suite 100 San Diego, CA 92121See details»
Organovo Holdings, Inc. Announces Pricing of $5.25 Million …
May 9, 2024 Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as …See details»
Corporate Governance | Organovo Holdings, Inc.
Corporate Governance. The Board of Directors of Organovo Holdings, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. …See details»
Organovo Holdings - Funding, Financials, Valuation & Investors
Organovo Holdings is registered under the ticker NASDAQ:ONVO . Their stock opened with $4.50 in its Feb 24, 2012 IPO. Organovo Holdings is funded by 4 investors. Eric …See details»
Organovo On Track to Establish Human 3D Disease Model in
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today provided a business overview and progress update, and announced it is …See details»
Organovo Holdings, Inc. (ONVO) - Stock Analysis
5 days ago Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.See details»
Organovo Data Presented at Digestive Disease Week (DDW2024 ...
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel …See details»
Organovo Data Presented at Digestive Disease Week (DDW2024 ...
4 days ago Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as …See details»
2024-05-21 | NDAQ:ONVO | Press Release | Organovo Holdings …
4 days ago Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as …See details»
FAQs | Organovo Holdings, Inc.
Organovo, Inc. was incorporated in 2007 to advance bioprinting technology and began its operations in San Diego, California in January 2009. What is the relationship between …See details»
Organovo Holdings Annual Report 2022
Organovo Holdings, Inc. (“Organovo Holdings,” “we,” “us,” “our,” the “Company” and “our Company”) is an early-stage biotechnology company that focuses on building high …See details»
Organovo Data Presented at Digestive Disease Week (DDW2024 ...
3 days ago SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing …See details»
Organovo Holdings, Inc. Announces Pricing of $5.25 Million
May 9, 2024 Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as …See details»
Organovo to Present Data on FXR314 at Digestive ... - Markets …
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel …See details»